TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04898257

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Multistrain probiotic
Description: After completion of screening phase, during baseline visit, eligible patients will be assigned to Lactibiane Tolerance® 10 billion CFU 1 capsule twice a day on an empty stomach (30 minutes before breakfast and 30 minutes before dinner).
Study: NCT02902185

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ART plus Chidamide
Description: Chidamide will be administrated 10mg each time, twice a week, interval not less than 3 days for 12 weeks.Antiretroviral therapy will be kept during entire study.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ART plus Placebo
Description: Placebo will be administrated 10mg each time, twice a week, interval not less than 3 days for 12 weeks.Antiretroviral therapy will be kept during entire study.
Study: NCT01802723

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug: salmeterol xinafoate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug: salmeterol xinafoate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug: salmeterol xinafoate
Study: NCT02367404

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pelvic Floor Muscle Training
Description: PMFT weekly for 3 months

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pelvic Floor Muscle Training
Description: PMFT weekly for 3 months
Study: NCT03256786

Intervention type: BEHAVIORAL
Intervention: Prewarming using forced air warmer, warmed intravenous fluid
Description: Combined modality active warming consisting of preoperative 15 min of surface warming using a forced air warmer before spinal anesthesia and coloading of warmed intravenous fluid in active warming group
Study: NCT01342614

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fosinopril
Description: Fosinopril group received fosinopril, 10mg, once per day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin group was treated with metformin hydrochloride, 500mg, three times per day
Study: NCT01496911

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levocetirizine
Description: a single oral dose of 5 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxyzine
Description: a single oral dose of 50 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: a single oral dose
Study: NCT02153814

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endometrial Scratch
Description: After cleansing the cervix with Betadine, the procedure will be performed using a 3mm endometrial sampling curette, with three passes made of the endometrium along the length of the fundus. Patients will be given the option to take ibuprofen 600mg one hour prior to the scheduled procedure. The first endometrial scratch procedure or sham procedure will be performed up to two weeks prior to expected menses, and the second endometrial scratch or sham procedure will be performed cycle day 5-11 of the stimulation cycle.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endometrial Scratch
Description: After cleansing the cervix with Betadine, the procedure will be performed using a 3mm endometrial sampling curette, with three passes made of the endometrium along the length of the fundus. Patients will be given the option to take ibuprofen 600mg one hour prior to the scheduled procedure. The first endometrial scratch procedure or sham procedure will be performed up to two weeks prior to expected menses, and the second endometrial scratch or sham procedure will be performed cycle day 5-11 of the stimulation cycle.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham procedure
Description: For the sham procedure, after cleansing the cervix with betadine, the endometrial sampling curette will be placed 2-3cm into the cervix without entering the uterine cavity
Study: NCT02378207

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: H4:IC31
Description: H4 contains Mtb antigens Ag85B and TB10.4

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: H56:IC31
Description: H56 contains Mtb antigens ESAT-6, and Rv2660c

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: BCG

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Control Sodium Chloride 0.9%
Study: NCT03783494

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Target control infusion with propofol
Description: Target control infusion with propofol for patients with indications of sustaining very painful orthopedic emergency emergent procedures
Study: NCT01802723

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug: Placebo
Study: NCT03211013

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oxytocin
Description: single-dose administration of OT nasal spray, complete computer-based tasks post-dose for approximately 1 hour

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: single-dose administration of OT nasal spray, complete computer-based tasks post-dose for approximately 1 hour

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: single-dose administration of placebo nasal spray, complete computer-based tasks post-dose for approximately 1 hour

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebos
Description: single-dose administration of placebo nasal spray, complete computer-based tasks post-dose for approximately 1 hour
Study: NCT05670509

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: administration of Nasal midazolam in home group as a rescue medication for seizure control.
Description: Children from home group assigned to receive treatment with intranasal midazolam with doses of 0.2 mg/kg (maximum, 10 mg) body weight of the standard IV formulation of midazolam (5mg/mL) via a metered dose sprayer at 0.1 mL/spray (i.e. 0.5 mg/spray). If the volume to be administered exceeded 1 mL, the dose was divided between both nostrils to avoid runoff and swallowing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: administration of Buccal midazolam in home group as a rescue medication for seizure control.
Description: Children from home group randomly assigned to receive treatment with buccal midazolam with doses of 0.2 mg/kg (maximum, 10 mg) body weight of the standard IV formulation of midazolam (5mg/mL) via dripping between the cheek and the gum per side using insulin syringe

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: administration of intramuscular midazolam in homegroup as a rescue medication for seizure control.
Description: Children from home group randomly assigned to receive treatment with intramuscular midazolam with doses of 0.2 mg/kg (maximum, 10 mg) body weight of the standard IV formulation of midazolam (5mg/mL) using 3 mm syringe in the front aspect of thigh

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: administration of Nasal midazolam in ER group as a rescue medication for seizure control.
Description: Children from the ER group assigned to receive treatment with intranasal midazolam with doses of 0.2 mg/kg (maximum, 10 mg) body weight of the standard IV formulation of midazolam (5mg/mL) via a metered dose sprayer at 0.1 mL/spray (i.e. 0.5 mg/spray). If the volume to be administered exceeded 1 mL, the dose was divided between both nostrils to avoid runoff and swallowing
Study: NCT01655979

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey Protein + Potassium bicarbonate
Description: 0.6 mmol WP/kg body weight + 90 mmol KHCO3 during bed rest

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey Protein + Potassium bicarbonate
Description: 0.6 mmol WP/kg body weight + 90 mmol KHCO3 during bed rest

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: Bed rest without dietary supplement

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: Bed rest without dietary supplement
Study: NCT05670509

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: administration of Buccal midazolam in ER group as a rescue medication for seizure control.
Description: Children from ER group randomly assigned to receive treatment with buccal midazolam with doses of 0.2 mg/kg (maximum, 10 mg) body weight of the standard IV formulation of midazolam (5mg/mL) via dripping between the cheek and the gum per side using insulin syringe
Study: NCT04309643

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTP-543
Description: Investigational Drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combined oral contraceptive containing Ethinyl estradiol (EE) and Levonorgestrel (LNG)
Description: Oral contraceptive in the form of 1 fixed combination tablet of Seasonique or generic equivalent (0.03 mg EE / 0.15 mg LNG)
Study: NCT01214161

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2% lidocaine gel
Description: Participants, after informed consent, will be randomized in a 1:1 ratio to the inert gel group or the intervention group. In the intervention group, after tenaculum placement, a Q-tip soaked in approximately 1mL of 2% lidocaine gel will be placed in the cervix up to the level of the internal cervical os. The Q-tip will be held there for 1 minute and then be removed. We will repeat the same procedure in the control group with an inert gel similar in appearance, color and consistency to the lidocaine gel.~Both the patient and the provider will be blinded to which gel was received. The research assistant will place the gel from its labeled tube into the unlabeled sterile tube in another room.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Participants, after informed consent, will be randomized in a 1:1 ratio to the inert gel group or the intervention group. In the intervention group, after tenaculum placement, a Q-tip soaked in approximately 1mL of 2% lidocaine gel will be placed in the cervix up to the level of the internal cervical os. The Q-tip will be held there for 1 minute and then be removed. We will repeat the same procedure in the control/placebo group with an inert gel similar in appearance, color and consistency to the lidocaine gel.~Both the patient and the provider will be blinded to which gel was received. The research assistant will place the gel from its labeled tube into the unlabeled sterile tube in another room.
Study: NCT02937779

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate
Description: tenofovir disoproxil fumarate 300 mg one tablet once daily from 24 weeks of amennorrhea to 6 weeks post-partum for HBe Ag positive women only.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rapid tests HBe Ag
Description: For all HBs Ag positive women
Study: NCT01511523

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: RGMA001
Description: 3 capsules administered BID once a day.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Sugar Pill
Description: Placebo
Study: NCT00462761

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC220
Description: Powder in bottle formulation supplied as 50mg or 350 mg in glass, crimped serum vials. Requires reconstitution by a pharmacist, and must be stored securely and protected from light.
Study: NCT01855633

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Traditional Theta burst stimulation (TBS)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Modified TBS rTMS
Study: NCT03893630

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Standard of Care
Study: NCT01512160

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04531083
Description: 2000 mg oral solution

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablets for Ibuprofen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04531083
Description: 1000 mg oral solution
Study: NCT01855633

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham rTMS
Study: NCT01263301

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: carotid duplex
Description: Carotid duplex in the differential diagnosis of subclavian steal syndrome due to Arteriovenous Hemodialysis access in the Ipsilateral arm

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: carotid duplex
Description: Carotid duplex in the differential diagnosis of subclavian steal syndrome due to Arteriovenous Hemodialysis access in the Ipsilateral arm
Study: NCT03889158

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Typhoid Vaccine
Description: All participants will receive the typhoid vaccine.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ascorbic Acid
Description: All participants will receive ascorbic acid.
Study: NCT00774228

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: I-ZIP Ocular Bandage

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Oasis 24 Hour Soft Shield Collagen Corneal Shield
Study: NCT04599374

Intervention type: OTHER
Intervention: no intervention
Description: This study collected data only without any intervention.

Intervention type: OTHER
Intervention: no intervention
Description: This study collected data only without any intervention.

Intervention type: OTHER
Intervention: no intervention
Description: This study collected data only without any intervention.

Intervention type: OTHER
Intervention: no intervention
Description: This study collected data only without any intervention.
Study: NCT00735774

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 11C-ORM-13070
Description: Single dose of i.v. solution
Study: NCT00605813

Intervention type: DRUG
Intervention: Sertraline hydrochloride
Description: J ZOLOFT® Tablets 25 mg and J ZOLOFT® Tablets 50 mg. J ZOLOFT is Brand name in Japan.~Dosage, Frequency: According to Japanese LPD, The usual initial dose of J ZOLOFT in adults is 25 mg daily as sertraline and then gradually increased up to 100 mg, which should be given orally once daily. The dose may be adjusted within the range not exceeding 100mg according to the patient's age and symptoms.~Duration: According to the protocol of A0501091, the duration of the investigation for findings regarding safety and efficacy of a patient is from the first drug administration to the 52 weeks after the first administration.
Study: NCT04136054

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adjusted group CBT-i for Depression, Anxiety and PTSD
Description: Adjusted group CBT-i for Depression, Anxiety and PTSD. CBT-i includes sleep scheduling/sleep compression, stimulus control, relaxation, cognitive interventions and sleep hygiene advice. Adjustments include the relationship between sleep and the psychiatric conditions at hand and and working with motivational enhancement techniques to increase adherence to treatment.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Care as usual wait-list control group
Description: Usual care at the clinic. This entails managing pharmacological treatment for the psychiatric problems and/or sleep problems. The clinic also provides different group treatments, such as mindfulness groups and CBT groups for symptoms of worry and depression, and individual therapy.
Study: NCT02393833

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Blood samples collection
Description: Blood samples to be collected at the following time points:~1. Baseline, (after the completion of induction chemotherapy and, if randomized to CM maintenance, before start of CM maintenance.)~2. Months 12, 18 and 36 after start of induction chemotherapy~3. At time of confirmatory evidence of progression

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood samples collection
Description: Blood samples to be collected at the following time points:~1. Baseline, (after the completion of induction chemotherapy and, if randomized to CM maintenance, before start of CM maintenance.)~2. Months 12, 18 and 36 after start of induction chemotherapy~3. At time of confirmatory evidence of progression
Study: NCT02207790

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2609

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2609

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2609

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2609

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: E2609 low-dose and placebo in healthy Japanese subjects, E2609 mid-dose and placebo in healthy Japanese subjects, E2609 high-dose and placebo in healthy Japanese subjects, E2609 mid-dose and placebo in healthy White subjects

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: E2609 low-dose and placebo in healthy Japanese subjects, E2609 mid-dose and placebo in healthy Japanese subjects, E2609 high-dose and placebo in healthy Japanese subjects, E2609 mid-dose and placebo in healthy White subjects

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: E2609 low-dose and placebo in healthy Japanese subjects, E2609 mid-dose and placebo in healthy Japanese subjects, E2609 high-dose and placebo in healthy Japanese subjects, E2609 mid-dose and placebo in healthy White subjects

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: E2609 low-dose and placebo in healthy Japanese subjects, E2609 mid-dose and placebo in healthy Japanese subjects, E2609 high-dose and placebo in healthy Japanese subjects, E2609 mid-dose and placebo in healthy White subjects
Study: NCT03047642

Intervention type: DIAGNOSTIC_TEST
Intervention: Biomarker assay
Description: There is no intervention on the patients but biomarker assays are being evaluated for their performance to distinguish bacterial infection from non-bacterial infections in febrile patients

Intervention type: DIAGNOSTIC_TEST
Intervention: Biomarker assay
Description: There is no intervention on the patients but biomarker assays are being evaluated for their performance to distinguish bacterial infection from non-bacterial infections in febrile patients

Intervention type: DIAGNOSTIC_TEST
Intervention: Biomarker assay
Description: There is no intervention on the patients but biomarker assays are being evaluated for their performance to distinguish bacterial infection from non-bacterial infections in febrile patients
Study: NCT02341807

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AAV2-hCHM
Description: Comparison of different dosages of AAV2-hCHM

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AAV2-hCHM
Description: Comparison of different dosages of AAV2-hCHM

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AAV2-hCHM
Description: Comparison of different dosages of AAV2-hCHM
Study: NCT00822068

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: anodal tDCS
Description: anodal transcranial direct current stimulation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: cathodal tDCS
Description: cathodal transcranial direct current stimulation

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: sham stimulation
Description: sham stimulation
Study: NCT01955161

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once daily, matching placebo capsules, orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idalopirdine
Description: Once daily, encapsulated tablets, orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idalopirdine
Description: Once daily, encapsulated tablets, orally
Study: NCT01614990

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Macimorelin
Description: Subjects will receive macimorelin (1 mg/kg) and matching placebo (Powerade®) daily for 7 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo (Powerade®) daily for 7 days.
Study: NCT00087711

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed
Description: 500 mg/m2, IV q 21 days x 6 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gemcitabine
Description: 1250 mg/m2, IV, day 1 and 8 q 21 days x 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: 75 mg/m2, IV, q 21 days x 6 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cisplatin
Description: 75 mg/m2, IV, q 21 days x 6 cycles
Study: NCT02959047

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alirocumab
Description: 150mg SQ every 2 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo
Description: SQ every 2 weeks
Study: NCT00119392

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil
Description: Given orally

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: yttrium Y 90 ibritumomab tiuxetan
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Description: Undergo transplantation
Study: NCT03654963

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Medication reconciliation
Description: Medication reconciliation is the systematic process described above.
Study: NCT00104299

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab plus cyclophosphamide placebo (rituximab group)
Description: 375 mg/m\^2 infusions once weekly for 4 week
Study: NCT01512160

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablets for Ibuprofen
Study: NCT00104299

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide plus rituximab placebo (control group)
Description: 2 mg/kg/day orally for months 1-3

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azathioprine
Description: 2 mg/kg/day orally for months 4-6

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone (or other glucocorticoid)
Description: 1 g/day intravenously for up to 3 days within 14 days prior to receiving rituximab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone (or other glucocorticoid)
Description: 1 g/day intravenously for up to 3 days within 14 days prior to receiving rituximab
Study: NCT01512160

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: 2 x 200 mg tablets

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo solution for PF-04531083

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo solution for PF-04531083

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets for Ibuprofen
Study: NCT01644617

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo rapidly dissolving tablets administered sublingually once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8237 6 DU
Description: MK-8237 6 DU rapidly dissolving tablets administered sublingually once daily